Direct-to-consumer genetic testing company 23andMe will stop sales of health-related tests following a warning letter from the Food and Drug Administration two weeks ago.
“23andMe has been giving consumers access to health information for six years and is committed to finding the right regulatory path for our customers,” CEO and founder Anne Wojcicki wrote in a statement on the company website Thursday. “I am highly disappointed that we have reached this point and will work hard to make sure consumers have direct access to health information in the near future. Our goal is to work cooperatively with the FDA to provide that opportunity.”
The goal of 23andMe is to provide consumers with direct access to their genetic information in an easy and affordable way. A test can be purchased online for $99, and provides reports on 254 different conditions and diseases.
However, the FDA expressed concerns that the company was selling its product as a diagnostic test for health risks. The agency said 23andMe must gain government authorization before continuing to market the product as a medical test.
The company will continue to provide ancestry information and raw data to consumers, but will put the sale of health-related results on hold.
Individuals who purchased genetic testing kits prior to when the FDA letter was sent on Nov. 22 will continue to have access to their full results. Those who purchased them on or after that date will only receive ancestry information and raw data, and will be eligible for a refund.
Wojcicki emphasized that the company stands by their data, noting that the samples are sent to CLIA certified labs — the same standards used for most health-related tests.
“The information 23andMe provides is incredibly accurate,” 23andMe spokeswoman Catherine Afarian told National Journal in early November. “If we tell you you’re a C-C there, you are. From there, the next step is interpretation — what does science know about it?”
This is where the results become less clear.
As National Journal previously reported, there is a significant amount of uncertainty regarding the interpretation side of these test results. The concern is that individuals may make important medical decisions based on results that are constantly changing and that even experts don’t completely understand.
The company will continue to move forward with the FDA’s regulatory review process, and hopes to resume offering health-related information shortly.
What We're Following See More »
Newt Gringrich is actively positioning himself as a possible VP nominee for Donald Trump, according to National Review. After a New York Times piece mentioned him as a possible running mate, he said, "It is an honor to be mentioned. We need a new Contract with America to outline a 100-day plan to take back Washington from the lobbyists, bureaucrats, unions, and leftists. After helping in 1980 with Reagan and 1995 as speaker I know we have to move boldly and decisively before the election results wear off and the establishment starts fighting us. That is my focus." Meanwhile, Trump told CNN he'd be "interested in vetting" John Kasich as well.
"House Democrats are stepping up pressure on Republicans to advance legislation addressing Puerto Rico’s worsening debt crisis by issuing a report arguing that austerity cuts can’t be sustained and have made the island more vulnerable to the mosquito-borne Zika virus." Democrats on the House Natural Resources Committee released a report yesterday that argued "further sharp reductions in government spending can’t be a part of a legislative solution"—especially with a rainy season boosting the mosquito population and stressing an island health system already struggling to deal with the Zika virus.
"ISIS has the capability to stage a Paris-style attack in the U.S. using local cells to strike in multiple locations and inflict dozens of casualties, according to the Obama administration's top U.S. intelligence official." Director of National Intelligence James Clapper told CNN's Peter Bergen that such a scenario is "something we worry about a lot in the United States, that they could conjure up a raid like they did in Paris or Brussels."
"Donald J. Trump said on Wednesday that he expected to reveal his vice presidential pick sometime in July—before the Republican National Convention in Cleveland—but added that he would soon announce a committee to handle the selection process, which would include Dr. Ben Carson." He said he's inclined to name a traditional political figure, unlike himself.